Driver mutation detected in cerebrospinal fluid despite negative liquid biopsy results DOI Creative Commons
Kei Kunimasa,

Daisuke Aohara,

Kazumi Nishino

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 10, 2025

We report a case where KRAS G12V driver mutation was identified in cerebrospinal fluid (CSF) but not peripheral blood cell-free DNA (cfDNA) patient with advanced lung adenocarcinoma and significant central nervous system involvement. A 67-year-old man presented hemoptysis diagnosed stage IVB TTF-1-positive brain bone metastases. Standard chemotherapy ineffective. While cfDNA analysis detected only RAD21 mutation, CSF revealed the mutation. Despite identification, no effective targeted therapy available. This highlights that may be more suitable than for detecting mutations patients predominant CNS lesions.

Language: Английский

Driver mutation detected in cerebrospinal fluid despite negative liquid biopsy results DOI Creative Commons
Kei Kunimasa,

Daisuke Aohara,

Kazumi Nishino

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 10, 2025

We report a case where KRAS G12V driver mutation was identified in cerebrospinal fluid (CSF) but not peripheral blood cell-free DNA (cfDNA) patient with advanced lung adenocarcinoma and significant central nervous system involvement. A 67-year-old man presented hemoptysis diagnosed stage IVB TTF-1-positive brain bone metastases. Standard chemotherapy ineffective. While cfDNA analysis detected only RAD21 mutation, CSF revealed the mutation. Despite identification, no effective targeted therapy available. This highlights that may be more suitable than for detecting mutations patients predominant CNS lesions.

Language: Английский

Citations

0